
|Articles|May 1, 2004
Microplasmin receives orphan drug protection
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
NeuroOp Guru: When proptosis isn’t thyroid eye disease
3
Ophthalmic innovation by the decades: The 1980s and 1990s
4
FDA approves Rayner’s RayOne EMV Toric intraocular lens
5